---
title: "Immunovant | 8-K: FY2027 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295097935.md"
datetime: "2026-08-06T11:17:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295097935.md)
  - [en](https://longbridge.com/en/news/295097935.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295097935.md)
generator: "portal-rs"
---

# Immunovant | 8-K: FY2027 Q1 Revenue: USD 0

Revenue: As of FY2027 Q1, the actual value is USD 0.

EPS: As of FY2027 Q1, the actual value is USD -0.75, missing the estimate of USD -0.6319.

EBIT: As of FY2027 Q1, the actual value is USD -153.22 M.

Immunovant, Inc. filed a Form 8-K on August 6, 2026, announcing its financial results for the fiscal first quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. However, the Form 8-K document itself does not detail any specific financial or operational metrics, such as segment revenue, net income, gross margin, operating profit, operating costs, cash flow, or other company-specific financial indicators. Additionally, the document does not include any forward-looking statements or guidance regarding future financial performance or operational outlook.

### Related Stocks

- [IMVT.US](https://longbridge.com/en/quote/IMVT.US.md)

## Related News & Research

- [Immunovant director Atul Pande disposes of 1,500 common shares worth $64,905](https://longbridge.com/en/news/297366091.md)
- [Bank of New York Mellon Corp Acquires New Stake in Immunovant, Inc. $IMVT](https://longbridge.com/en/news/297746838.md)
- [Gaming and Leisure Properties declares Q3 2026 dividend of $0.82 per share](https://longbridge.com/en/news/297652371.md)
- [Ethero reports 5,717,657 shares outstanding, 7,457,019 voting rights as of August 2026](https://longbridge.com/en/news/297803164.md)
- [Americold Realty Trust declares Q3 2026 dividend of R$ 0.27 per unit](https://longbridge.com/en/news/297823075.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**